The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

30. Juni 2022

Regulatory

Biosergen successfully completes second cohort of BSG005 phase I trial

Release
28. Juni 2022

Regulatory

Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB

Release
07. Juni 2022

Regulatory

Biosergen publishes 2021 Annual report

Release
31. Mai 2022

Regulatory

Biosergen publishes interim report for first quarter 2022

Release
2022-Q1 Financial Report
13. Mai 2022

Regulatory

Biosergen successfully completes first cohort of BSG005 phase I trial

Release
07. April 2022

Regulatory

The first subject has been dosed in the phase I trial of BSG005

Release
31. März 2022

Regulatory

Biosergen publishes interim report for fourth quarter 2021

Biosergen Q4 financial report press release
Q4-2021 Financial Report
30. November 2021

Regulatory

Biosergen publishes interim report for the third quarter 2021

Q3-2021 Financial Report
Biosergen Q3 financial report press release
31. August 2021

Regulatory

Biosergen publishes interim report for the second quarter 2021

Q2-2021 Financial Report
Biosergen Q2 report press release
27. Juni 2021

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Release
08. Juni 2021

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Biosergens offering fully subscribed